» Articles » PMID: 30373585

Effect of COPD on Symptoms, Quality of Life and Prognosis in Patients with Advanced Non-small Cell Lung Cancer

Overview
Journal BMC Cancer
Publisher Biomed Central
Specialty Oncology
Date 2018 Oct 31
PMID 30373585
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Many studies have reported the prevalence of chronic obstructive pulmonary disease (COPD) and its effects and prognosis in patients with lung cancer, but few have considered quality of life and survival of patients with lung cancer according to severity of airway obstruction. This study investigated the presence of COPD and the severity of airway obstruction in patients with non-small cell lung cancer (NSCLC), and analyzed how these factors affected symptoms, quality of life, and prognosis.

Methods: We retrospectively reviewed the prospective lung cancer database of the Catholic Medical Centers at the Catholic University of Korea from 2014 to 2017. We enrolled patients with advanced NSCLC and evaluated quality of life using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30. We also estimated pulmonary function and analyzed survival data.

Results: Of the 337 patients with advanced NSCLC, 170 (50.5%) had COPD and 167 (49.5%) did not. Significant differences were observed in symptoms between the two groups. The COPD group complained of more symptoms, such as cough, sputum, and dyspnea, than those in the non-COPD group. The distribution according to the severity of obstruction in the COPD group was as follows: Grade 1 (FEV ≥ 80%) 35 patients (20.6%), Grade 2 (50% ≤ FEV < 80%) 103 patients (60.6%), Grade 3 (30% ≤ FEV < 50%) 24 patients (14.1%), and Grade 4 (FEV < 30%) 8 patients (4.7%). The presence of COPD did not affect overall quality of life in patients with NSCLC, but as the airway obstruction increased, physical function decreased, and fatigue and dyspnea were more frequent. The overall median survival of the COPD group was shorter than that of the non-COPD group (median survival, 224 vs. 339 days, p = 0.035).

Conclusions: In this study, a high prevalence of COPD was found among patients with advanced NSCLC, and COPD patients complained about various symptoms and had diminished quality of life in several sectors. Therefore, it is necessary to actively evaluate quality of life, lung function, and symptoms in patients with lung cancer and reflect them in the treatment and management plans of these patients.

Citing Articles

The Impact of Immune-Related Adverse Event Severity on Prognosis in Elderly Patients With Nonsmall-Cell Lung Cancer in First-Line Immune Checkpoint Inhibitor Treatment.

Miyamoto I, Shimizu T, Hanamura M, Mizuno Y, Nakayama R, Kusahana R Thorac Cancer. 2025; 16(3):e70006.

PMID: 39901355 PMC: 11790473. DOI: 10.1111/1759-7714.70006.


Metabolic pathways from the gut metatranscriptome are associated with COPD and respiratory function in lung cancer patients.

Dora D, Revisnyei P, Mihucz A, Kiraly P, Szklenarik G, Dulka E Front Cell Infect Microbiol. 2024; 14:1381170.

PMID: 39635041 PMC: 11616033. DOI: 10.3389/fcimb.2024.1381170.


Symptom clusters and symptom network analysis during immunotherapy in lung cancer patients.

Yang X, Bai J, Liu R, Wang X, Zhang G, Zhu X Support Care Cancer. 2024; 32(11):717.

PMID: 39382716 DOI: 10.1007/s00520-024-08918-0.


Is There a Link between Chronic Obstructive Pulmonary Disease and Lung Adenocarcinoma? A Clinico-Pathological and Molecular Study.

Lunardi F, Nardo G, Lazzarini E, Tzorakoleftheraki S, Comacchio G, Fonzi E J Pers Med. 2024; 14(8).

PMID: 39202030 PMC: 11355616. DOI: 10.3390/jpm14080839.


Alteration of the gut microbiota in patients with lung cancer accompanied by chronic obstructive pulmonary diseases.

Wang T, Su W, Li L, Wu H, Huang H, Li Z Heliyon. 2024; 10(9):e30380.

PMID: 38737249 PMC: 11088322. DOI: 10.1016/j.heliyon.2024.e30380.


References
1.
Braun D, Gupta D, Staren E . Quality of life assessment as a predictor of survival in non-small cell lung cancer. BMC Cancer. 2011; 11:353. PMC: 3171386. DOI: 10.1186/1471-2407-11-353. View

2.
Grutters J, Joore M, Wiegman E, Langendijk J, De Ruysscher D, Hochstenbag M . Health-related quality of life in patients surviving non-small cell lung cancer. Thorax. 2010; 65(10):903-7. DOI: 10.1136/thx.2010.136390. View

3.
Bae J, Gwack J, Park S, Shin H, Chang S, Yoo K . [Cigarette smoking, alcohol consumption, tuberculosis and risk of lung cancer: the Korean multi-center cancer cohort study]. J Prev Med Public Health. 2007; 40(4):321-8. DOI: 10.3961/jpmph.2007.40.4.321. View

4.
Vestbo J, Hurd S, Rodriguez-Roisin R . The 2011 revision of the global strategy for the diagnosis, management and prevention of COPD (GOLD)--why and what?. Clin Respir J. 2012; 6(4):208-14. DOI: 10.1111/crj.12002. View

5.
Ban W, Lee J, Ha J, Yeo C, Kang H, Rhee C . Dyspnea as a Prognostic Factor in Patients with Non-Small Cell Lung Cancer. Yonsei Med J. 2016; 57(5):1063-9. PMC: 4960370. DOI: 10.3349/ymj.2016.57.5.1063. View